Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Glucagon-like peptide 1 (GLP-1)

Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans…. Molecular Metabolism 2019

Document identifier
CEI-BR-078
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ
Title
Glucagon-like peptide 1 (GLP-1)
Source
Molecular Metabolism
Year
2019
Volume, issue, pages
30:72–130
Digital object identifier
10.1016/j.molmet.2019.09.010
PubMed identifier
31767182
Record type
Journal article
Institute identifier
CEI-BR-078

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: RetatrutideCompound monograph
Monograph: SurvodutideCompound monograph
Monograph: MazdutideCompound monograph
Monograph: EcnoglutideCompound monograph
Monograph: TeduglutideCompound monograph
Synthesis: Retatrutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Survodutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Mazdutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Mazdutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier…Evidence synthesis
Synthesis: Retatrutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Retatrutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Survodutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Mazdutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Mazdutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier…Evidence synthesis
Synthesis: Retatrutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Retatrutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Survodutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Mazdutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Mazdutide in type 2 diabetes mellitus: durability of effectEvidence synthesis
Synthesis: Teduglutide in inflammatory bowel disease and mucosal barrier…Evidence synthesis
22 citing documents.

§1.3Subject tags

glp-1 mechanism review

Compound Evidence Institute · CEI-BR-078 · https://compoundevidence.com/bibliography/muller2019/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.